SociéTIC Analyse d'affaires

4 November 2017

Lumed Joins Forces with bioMérieux to Fight Bacterial Resistance


This past October 25, Sherbrooke computer engineering firm, Lumed, whose mission is to optimize clinical practice, the use of antimicrobials, and the quality of patient care, established an international partnership with bioMérieux. The latter company has offices around the world, providing diagnostic solutions, and has proven to be a major player in in-vitro diagnostics. The goal of this partnership is to help hospitals fight bacterial resistance to antimicrobials.

This partnership will enable both companies to collaborate in the sales and distribution of Lumed’s expert Antimicrobial Prescription Surveillance System (APSS) and DATA software in Europe, Canada, and the United States.

Lumed is a spin-off business from the Accélérateur de création d’entreprises technologiques (ACET—Accelerator for the Creation of Technological Businesses) and has benefited from a partnership with the Université de Lyon and the Université de Sherbrooke, which enabled it to quickly reinforce its ties with bioMérieux.

Lumed welcomes bioMérieux to its capital structure as a strategic investor. This investment completes the funding cycle started earlier this year with the participation of various partners, including ACET Capital, the Business Development Bank of Canada, Desjardins, Canada Economic Development for Quebec Regions, and Can-Export.

APSSThe appropriate use of antibiotics is vital to ensure appropriate patient case management, to control hospital pharmacy expenses, and to reduce bacterial resistance. Lumed’s APSS product is intelligent, clinical decision-making support software that helps hospital teams in charge of managing antibiotics by enabling them to follow the progress of patients’ clinical information, as soon as it becomes available. In a recently published study, the implementation of APSS software was shown to reduce the use of antimicrobials by more than 20% over a three-year period.

The worldwide introduction of APSS by bioMérieux, in collaboration with Lumed, will solidify the company’s leadership position in the fight against antimicrobial resistance by working in close collaboration with hospitals.

» For more details



» This week, I’m at… LUMED

Back to the news

Leave a Reply

Your email address will not be published. Required fields are marked *

Sherbrooke Innopole’s mandate ends on March 31, 2024. We invite you to contact Entreprendre Sherbrooke or the Service du développement économique of the Ville de Sherbrooke for further services.
Thank you to all Sherbrooke industrial and technological businesses, as well as to all our partners for the trust granted since 2009!